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Summary 
Although the mechanism of mammalian apoptosis has 
not been elucidated, a protease of the CED-3/ICE fam- 
ily is anticipated to be a component of the death ma- 
chinery. Several lines of evidence predict that this pro- 
tease cleaves the death substrate poly(ADP-ribose) 
polymerase (PARP) to a specific 85 kDa form observed 
during apoptosis, is inhibitable by the CrmA protein, 
and is distinct from ICE. We cloned a ced.3/ICE-related 
gene, designated Yama, that encodes a protein identi- 
cal to CPP32p. Purified Yama was a zymogen that, 
when activated, cleaved PARP to generate the 85 kDa 
apoptotic fragment. Cleavage of PARP by Yama was 
inhibited by CrmA but not by an inactive point mutant 
of CrmA. Furthermore, CrmA blocked cleavage of 
PARP in cells undergoing apoptosis. We propose that 
Yama may represent an effector component of the 
mammalian cell death pathway and suggest that CrmA 
blocks apoptosis by inhibiting Yama. 
Introduction 
Apoptosis or programmed cell death (PCD) is of funda- 
mental importance to biological processes ranging from 
embryogenesis to the development of the immune system 
(Ellis et al., 1991). Although the mechanism of mammalian 
PCD is not understood, three lines of evidence indicate 
that a protease is a component of the mammalian cell 
death pathway. First, investigations of PCD in the nema- 
tode Caenorhabditis elegans identified a gene, ced-3, that 
is essential for apoptosis (Ellis and Horvitz, 1986). Cloning 
and sequencing of ced-3 revealed that it encodes a protein 
having homology to interleukin-llB (IL-lJ3)-converting en- 
zyme (ICE) (Yuan et al., 1993), a mammalian Cys protease 
that processes pro-lL-113 to an active form by proteolytic 
cleavage at Asp residues (Thornberry et al., 1992; Cerretti 
et al., 1992). Initial reports suggested that ICE might be 
the functional mammalian homolog of ced-3, since overex- 
pression of ICE induced apoptotic changes in Rat-1 cells 
(Miura et al., 1993). However, the recent analysis of mice 
with germline inactivation of ICE indicated that this is not 
the case, as these mice developed normally, with no obvi- 
ous defects in apoptosis (Li et al., 1995). Given the compel- 
ling evidence that CED-3 is a death protease in C. elegans, 
however, it appears likely that there may be another mam- 
malian protease that plays a key role in mammalian apop- 
tosis. 
A second independent line of evidence for protease 
involvement in mammalian PCD comes from experiments 
utilizing the cowpox virus CrmA protein, an inhibitor of ICE 
(Ray et al., 1992). Expression of CrmA was found to inhibit 
apoptosis in a wide range of systems, including PCD initi- 
ated by nerve growth factor withdrawal in primary chicken 
neuronal cultures (Gagliardini et al., 1994), by activation 
of either Fas or the tumor necrosis factor (TNF) receptor 
(Tewari and Dixit, 1995), by serum withdrawal in Rat-1 
fibroblasts (Wang et al., 1994), and by detachment of 
mammary epithelial cells from the underlying extracellular 
matrix (Boudreau et al., 1995). This provides strong evi- 
dence for a CrmA-inhibitable ICE-like protease in the cell 
death pathway. The criterion that the death enzyme is 
CrmA inhibitable is important as it allows one to discount 
ICE family members such as ICH-1 that, when overex- 
pressed, do induce apoptosis but appear not to be inhibit- 
able by CrmA (Wang et al., 1994). 
A third line of support for the activation of a protease 
during mammalian PCD comes from the study of a death 
substrate specifically cleaved during apoptosis. Kauf- 
mann (1989) and colleagues (Kaufmann et al., 1993) found 
that the 116 kDa nuclear protein poly(ADP-ribose) poly- 
merase (PARP) was specifically cleaved to produce an 85 
kDa fragment in many forms of PCD, including that in- 
duced by chemotherapeutic drugs in cell lines and by dexa- 
methasone in thymocytes. Further analysis by Lazebnik 
et al. (1994) using a cell-free system demonstrated that the 
cleavage occurred C-terminal to Asp and that the protease 
responsible resembled ICE in its susceptibility ochemical 
inhibitors, but was distinct from ICE, since purified ICE 
did not cleave PARP. Hence, an anticipated characteristic 
of the death protease is that it should cleave the death 
substrate PARP to generate the specific 85 kDa fragment 
observed during apoptosis. 
Taken together, the data predict the existence of a mam- 
malian protease that is a member of the CED.3/ICE family 
of Asp-specific Cys proteases, that cleaves the death sub- 
strate PARP to generate a specific 85 kDa apoptotic frag- 
ment, and that is susceptible to inhibition by CrmA. With 
this in mind, we adopted an approach of systematically 
cloning, expressing, and purifying mammalian members 
of the ced-3/ICE gene family and determining whether they 
possessed the above properties. We cloned a cDNA, des- 
ignated Yama (after the Hindu god of death), which was 
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Figure 1. Cleavage of PARP by Activated Yama 
(A) Yama is a protease zymogen that, upon activation, cleaves PARP 
in vitro to the 85 kDa apoptotic fragment. 
(Top) Hiss-tagged Yama was expressed and labeled using [3sS]Met in 
an in vitro transcription/translation reaction and purified by ion ex- 
change and nickel chelate affinity chromatography as described in 
Experimental Procedures. In vitro reactions were assembled in which 
0.586 ~g of purified PARP was incubated for 2 hr at 37°C with either 
buffer only (lane 1), ICE (lane 2), pu rifled pro-Yama (lane 3), or purified 
pro-Yama after activation with ICE (lane 4). Following incubation, one 
fifth of each reaction was analyzed by $DS-PAGE and immunoblotting 
using monoclonal antibody C-2-10 directed against PARP. Whole-cell 
lysates from B JAB cells undergoing anti-Fas-induced apoptosis (lane 
5) or from untreated B JAB cells (lane 6) were run alongside the in vitro 
reaction samples. 
(Bottom) Equal quantities of the in vitro reactions represented in lanes 
1-4 in the top panel were resolved by SDS-PAGE, and the dried gel 
was subjected to phosphorimager analysis to assess the state of the 
radiolabeled Yama protein. The closed arrow indicates the migration 
of purified pro-Yama, which is designated as the full-length p32 form. 
The open arrows indicate the wo major proteolytic fragments observed 
after activation of pro-Yama by ICE and are presumed to correspond 
to the putative p20 and pl 1 subunits predicted from cleavage t Asp 
residues in pro-Yama. 
(B) Cleavage of PARP to an 85 kDa fragment is a characteristic feature 
of both Fas- and TNF-induced apoptosis. 
almost identical to the cDNA encoding CPP3213 identified 
independently by Fernandes-Alnemri et al. (1994). We 
demonstrate that purified Yama is a zymogen that, upon 
activation, assumes a proteolytically competent form that 
cleaves PARP to the signature 85 kDa apoptotic fragment. 
Furthermore, we show that the proteolytic activity of Yama 
is inhibited by purified CrmA but not by an equivalent quan- 
tity of an inactive point mutant of CrmA. Taken together, 
the results indicate that Yama possesses the expected 
properties detailed above of the mammalian death prote- 
ase. Finally, in keeping with the in vitro results, we found 
that CrmA blocked the proteolytic cleavage of PARP in 
cells induced to undergo apoptosis. We propose that 
Yama represents a candidate for the effector protease of 
the mammalian cell death pathway and suggest that CrmA 
may block apoptosis by inhibiting the proteolytic activity 
of Yama. 
Results 
To identify genes related to ced-3, we took advantage of 
the conservation of the pentapeptide motif QACRG that 
encompasses the catalytic site Cys of ICE and is con- 
served among members of the CED-3/ICE protein family 
(Yuan et al., 1993). We adopted two approaches to identify 
related genes: one involved the use of degenerate poly- 
merase chain reaction (PCR) primers encoding the 
QACRG motif, and the other was to search the GenBank 
database of human expressed sequence tags (ESTs). The 
results of the latter approach are described here. We iden- 
tified an EST (T10341; deposited by M. Bento Soares) 
that, when translated, generated an open reading frame 
containing the QACRG motif. Using the cDNA correspond- 
ing to this EST as a probe, we screened a human umbilical 
vein endothelial cell library and cloned a cDNA encoding 
an open reading frame of 277 amino acids, designated 
Yama, that had homology to the CED-3/ICE family of pro- 
teins (data not shown). Soon thereafter, Fernandes- 
Alnemri et al. (1994) reported the cloning of a cDNA desig- 
nated CPP32,8 that had an almost identical open reading 
frame. 
We proceeded to determine whether Yama/CPP3213 
was indeed a protease and whether it fulfilled the require- 
ments predicted for a death protease. The amino acid se- 
quence suggested that it would be an Asp-specific Cys 
protease, as the residues thought to be important for Asp 
specificity in ICE are conserved in Yama (Walker et al., 
1994; Wilson et al., 1994; Fernandes-Alnemri et al., 1994). 
Yama was expressed in vitro as a fusion to a His6 purifica- 
tion tag at the N-terminus and isolated by ion exchange 
and nickel chelate affinity chromatography to determine 
(Top) B JAB cells were either left untreated (UnRx) or treated with 
agonist anti-Fas antibody (250 ng/ml) for the indicated time periods, 
and cell lysates were prepared and analyzed by immunoblotting using 
anti-PARP monoclonal antibody C-2-10 as described in Experimental 
Procedures. 
(Bottom) MCF7 cells were either left untreated (UnRx) or treated with 
recombinant TNF (40 ng/ml) for the indicated time periods, and cell 
lysates were similarly analyzed. 
Yama/CPP32~ Cleaves the Death Substrate PARP 
803 
whether it possessed proteolytic activity capable of cleav- 
ing PARP. The full-length, p32 form of purified Yama had 
no proteolytic activity against PARP (Figure 1A, top, lane 
3) and was thus designated pro-Yama. This result was 
not surprising, as ICE itself is a zymogen that requires 
proteolytic processing to a two-subunit form (p20 and p l0  
subunits) possessing proteolytic activity. The predicted 
amino acid sequence of Yama suggested that it, too, might 
be activated by proteolytic cleavage at Asp residues to 
generate a catalytically active enzyme (Fernandes- 
Alnemri et al., 1994). We found that purified ICE was able 
to cleave pro-Yama to yield two major products (Figure 
1A, bottom, lane 4; putative p20 and p l l  subunits are 
indicated by open arrows) and, more importantly, that 
Yama activated in this manner acquired proteolytic activity 
and cleaved PARP to the 85 kDa apoptotic form (Figure 
1A, top, lane 4). Purified ICE did not cleave PARP (Figure 
1A, top, lane 2), confirming earlier results (Lazebnik et al., 
1994) and excluding the possibility that PARP cleavage 
was mediated by the added ICE. Given the interest of 
our laboratory in the mechanism of Fas- and TNF-induced 
apoptosis (Tewari and Dixit, 1995), we investigated 
whether PARP cleavage occurred in these cell death sys- 
tems and whether the cleavage product was analogous 
to that observed in the in vitro experiments. Activation of 
either Fas (in BJAB lymphoma cells) or TNF receptors (in 
MCF7 breast carcinoma cells) induced PARP cleavage to 
the signature 85 kDa form (Figure 1B), and this product 
comigrated with the PARP cleavage fragment generated 
by purified Yama (Figure 1A, top, lanes 4 and 5). Thus, 
we concluded that Yama is a protease that cleaves PARP 
to the signature 85 kDa apoptotic fragment. 
Since the mammalian cell death protease is expected 
to be susceptible to inhibition by CrmA, we asked whether 
Yama was CrmA inhibitable. To address this question de- 
finitively, we used purified proteins to reconstitute the 
PARP cleavage reaction in vitro such that purified recom- 
binant CrmA protein could be added. To serve as a control, 
we designed a point mutant of CrmA, using as a guide 
results from mutational and structural analyses of mem- 
bers of the serpin family of protease inhibitors, a protein 
family of which CrmA is a member. Mutant CrmA carries 
a single amino acid substitution of Arg for Thr at amino 
acid 291 (Figure 2A). The corresponding residue in other 
inhibitory serpins is typically a small, uncharged residue 
and occupies a key position in the reactive site loop, which 
is a surface loop critically important for protease inhibitory 
function. Mutation of this residue to a charged residue in 
the serpins antitrypsin (Schulze et al., 1991; Hood et al., 
1994), plasminogen activator inhibitor I (Lawrence et al., 
1994) and C1 inhibitor (Davis et al., 1992) caused loss of 
inhibitory activity without significantly disrupting protein 
conformation. Hence, we expected that a similar mutation 
in CrmA would inactivate its protease inhibitory activity 
while allowing it to retain its native conformation. Both 
CrmA and mutant CrmA proteins were expressed as His6- 
tagged fusion proteins in Escherichia coli and purified by 
nickel chelate affinity chromatography (data not shown). In 
vitro characterization of the mutant CrmA protein revealed 
that under conditions in which CrmA bound and inhibited 
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Figure 2. Biochemical Characterization f Wild-Type CrmA and Mu- 
tant CrmA Proteins 
(A) A point mutation in the reactive site loop of CrmA inactivates its 
ability to inhibit ICE. (Top) The reactive site loop sequences of CrmA 
and mutant CrmA are compared. Amino acid 291 of wild-type CrmA, 
which corresponds to a critical reactive site loop residue in other ser- 
pins, was altered from Thr to Arg by site-directed mutagenesis. (Bot- 
tom) Both proteins were expressed in E. coil as His6 fusions and puri- 
fied as described in Experimental Procedures. Aliquots (44 rig) of ICE 
were titrated with the indicated amounts of purified CrmA protein (open 
squares) or mutant CrmA protein (closed circles). Residual ICE ctivity, 
expressed as the ratio ofthe inhibited rate (vi) to the uninhibited rate 
(Vo), was determined with a chromogenic ICE substrate and plotted 
against the quantity of CrmA or mutant CrmA protein added. ICE activ- 
ity was abolished by as little as 300 ng of CrmA, whereas no inhibition 
was detected with mutant CrmA, even using 30 lag, representing a 
500-fold molar excess over the enzyme. 
(B) Mutant CrmA does not form a complex with ICE. [aS]Met-labeled 
CrmA or mutant CrmA proteins were produced by coupled transcrip- 
tion/translation oftheir respective genes. The indicated amounts of ICE 
were added directlyto the diluted lysates and incubated as described in 
Experimental Procedures, following which samples were resolved by 
nondenaturing PAGE and the radioactive signals detected using a 
phosphorimager. Mutant CrmA failed to form a complex with ICE; 
indeed, ICE appeared to have no effect on this protein. In comparison, 
part of the wild-type CrmA formed a complex whereas the rest was 
cleaved in a manner that typifies the interaction of ICE with CrmA 
(Komiyama et al., 1994b). 
(C) The tertiary structures of CrmA and mutant CrmA proteins are 
indistinguishable as assessed by TUG-PAGE. [3sS]Met-labeled CrmA 
and mutant CrmA proteins were generated by coupled transcription/ 
translation and analyzed by TUG-PAGE as described n Experimental 
Procedures. The gels were dried and analyzed using a phosphorim- 
ager to detect the unfolding signature of ach protein. No difference 
in the signatures was observed, indicating that the point mutation in 
mutant CrmA did not disrupt the tertiary structure of he protein. 
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Figure 3. Cleavage of PARP by Activated Yama In Vitro Is Inhibitable 
by CrmA but Not by an Equivalent Amount of Mutant CrmA 
(Top) [35S]Met-labeled Yama was generated, purified, and activated 
by ICE as described in Experimental Procedures. Purified, activated 
Yama was then incubated for 2 hr at 37°C with 0.586 ~g of purified 
PARP in the presence of either buffer (lane 1), 270 pmol of CrmA 
(lane 2), or 270 pmol of mutant CrmA (lane 3) protein as described in 
Experimental Procedures. Following the incubation with PARP, one 
fifth of each reaction was analyzed by immunoblotting using anti-PARP 
monoclonal antibody C-2-10. 
(Bottom) Equivalent amounts of each of the above reactions were 
subjected to SDS-PAGE, and the dried gel was analyzed using a 
phosphorimager to assess the state of the labeled Yama protein. The 
open arrows indicate the position of the two major products that were 
observed in preparations of activated Yama and that are presumed 
to correspond to the putative p20 and p l l  subunits predicted from 
the amino acid sequence of Yama. 
ICE, the mutant protein neither bound ICE (Figure 2B) nor 
inhibited its proteolytic activity (Figure 2A). The tertiary 
structure of mutant CrmA, however, was not significantly 
altered by the point mutation, as its conformational signa- 
ture was indistinguishable from that of wild-type CrmA by 
transverse urea gradient-polyacrylamide gel electropho- 
resis (TUG-PAGE) (Figure 2C), a method used to probe 
the tertiary structures of serpins (Goldenberg, 1989; Mast 
et al., 1991; Komiyama et al., 1994a). 
Using these purified recombinant proteins, we found 
that CrmA markedly inhibited the cleavage of PARP by 
Yama in vitro (Figure 3). When CrmA was replaced with an 
equivalent amount of mutant CrmA protein, no inhibition of 
PARP cleavage was observed (Figure 3), indicating that 
the effect of CrmA was a function specifically of its ability 
to act as a protease inhibitor. 
To confirm that CrmA directly interacts with Yama, we 
examined the ability of either pro-Yama or activated Yama 
to form a complex with either native CrmA or mutant CrmA. 
Pro-Yama and activated Yama (both labeled with [~S]Met) 
were each incubated with either native CrmA or an equiva- 
lent amount of mutant CrmA recombinant protein. Each 
reaction was subjected to immunoprecipitation analysis 
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Figure 4. CrmA Directly Interacts with Activated Yama but Not with 
Pro-Yama 
(A) Phosphorimager scan of reaction samples prior to immunoprecipi- 
tation analysis. Reactions (80 Id) were assembled in which either radio- 
labeled pro-Yama (lanes 1 and 3) or radiolabeled activated Yama 
(lanes 2 and 4) were mixed with either 358 pmol of CrmA (lanes 1 and 
2) or 358 pmol of mutant CrmA (lanes 3 and 4) recombinant proteins. 
An aliquot (10 Id) of each reaction was resolved by SDS-PAGE, and 
pro-Yama or activated Yama was detected by phosphorimaging analy- 
sis. The closed arrow indicates the migration of pro-Yama (p32), 
whereas the open arrows indicate the putative p2O and p l l  subunits 
of activated Yama. 
(B) Immunoprecipitation of reaction samples with a polyclonal CrmA 
antiserum. An aliquot (35 ~1) of each of the above reactions was sub- 
jected to immunoprecipitation using a rabbit polyclonal CrmA antise- 
rum as described in Experimental Procedures. Immunoprecipitates 
were resolved by SDS-PAGE, and radiolabeled proteins were de- 
tected using a phosphorimager. The open arrows indicate the putative 
p20 and p l l  subunits of activated Yama. 
using a polyclonal CrmA antiserum, and the immunopre- 
cipitates were resolved by SDS-PAGE and visualized by 
phosphorimaging. CrmA formed a complex with the acti- 
vated two-subunit form of Yama but not with pro-Yama 
(Figure 4B). Mutant CrmA bound neither activated Yama 
nor pro-Yama (Figure 4B). We concluded that CrmA inter- 
acts directly with activated Yama to form an inhibitory 
complex. 
Since CrmA inhibited the cleavage of PARP by Yama 
in vitro, we inferred that if Yama is indeed responsible 
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Figure 5. CrmA, but Not Mutant CrmA, Blocks PARP Cleavage In Vivo 
during Apoptosis 
(A) Expression of CrmA or mutant CrmA in stably transfected clones. 
(Left) Clonal B JAB cell lines stablytransfected with either vector control 
(V1 and V4), CrmA (CrmA2 and CrmA3), or m utant CrmA (CrmA mutant 
12 and CrmA mutant 17) expression constructs were analyzed by 
Western blotting using a CrmA antiserum. 
(Bight) Clonal MCF7 cell lines stably transfected with either vector 
control (V4), CrmA (CrmA2, CrmA3, and CrmA4), or mutant CrmA 
(CrmA mutant 1 and CrmA mutant 2) expression constructs were simi- 
larly analyzed. 
(B) PARP cleavage to the 85 kDa fragment during Fas-induced 
apoptosis is inhibited by CrmA but not by mutant CrmA. Clonal B JAB 
transfectants not expressing CrmA (V1 and V4), expressing CrmA 
(CrmA2 end CrmA3), or expressing mutant CrmA (CrmA mutant 12 
and CrmA mutant 17) were treated with agonist anti-Fas antibody (250 
ng/ml) for the indicated time periods (UnRx indicates untreated lane), 
and lysates were prepared and analyzed by Western blot using the 
enti-PARP moneclonal ntibody C-2-10. 
(C) PARP cleavage to the 85 kDa fragment during TNF-induced 
apeptosis is inhibited by CrmA but not by mutant CrmA. Clonal MCF7 
transfectants not expressing CrmA (V4 and CrmA2), expressing CrmA 
(CrmA3 and CrmA4), or expressing mutant CrmA (CrmA mutant 1 and 
CrmA mutant 2) were treated with TNF (40 ng/ml) for the indicated 
time periods (UnRx indicates untreated lane), and lysates were pre- 
pared and analyzed by Western blot using the anti-PARP monoclonal 
antibody C-2-10. 
for PARP cleavage during apoptosis, then CrmA should 
inhibit PARP cleavage in vivo. To investigate this, we uti- 
lized MCF7 breast carcinoma and BJAB lymphoma cell 
lines stably transfected with either vector, CrmA (Tewari 
and Dixit, 1995), or mutant CrmA expression constructs. 
Clonal cell lines that expressed the indicated proteins were 
selected, and protein expression was confirmed by immu- 
noblotting using an anti-CrmA polyclonal antiserum (Fig- 
ure 5A). In keeping with the in vitro findings, expression 
of CrmA inhibited proteolytic leavage of PARP to the sig- 
nature 85 kDa fragment normally generated during 
apoptosis induced by either Fas (BJAB cells) or TN F recep- 
tors (MCF7 cells), whereas in the vector and mutant CrmA 
lines, cleavage of PARP proceeded unabated (Figures 5B 
and 5C). 
To investigate whether the in vivo blockade of PARP 
cleavage by CrmA and lack thereof by mutant CrmA corre- 
lated with the ability of these proteins to inhibit apoptosis, 
we examined the BJAB and MCF7 transfectants for their 
sensitivity to Fas- and TNF-induced apoptosis. Among 
MCF7 transfectants, CrmA afforded protection from TNF- 
induced apoptosis as expected, whereas mutant CrmA- 
expressing lines showed no protection and were as sensi- 
tive as a vector-transfected line (Figure 6, bottom). The 
protection conferred by CrmA and lack thereof by mutant 
CrmA was readily apparent on examination of nuclear mor- 
phology of propidium iodide-stained cells (Figure 6, top). 
When BJAB transfectants were examined for sensitivity to 
Fas-induced PCD, CrmA was protective, whereas mutant 
CrmA-expressing lines remained as sensitive as a vector 
control line (Figure 6, bottom). Thus, we concluded that 
the divergent abilities of CrmA and mutant CrmA to block 
PARP cleavage correlate with the abilities of these pro- 
teins to block cell death. 
Discussion 
The studies described herein were initiated to identify a 
mammalian CED-3-1ike protease that cleaved PARP to its 
signature 85 kDa apoptotic fragment and that was also 
inhibitable by CrmA. The data presented indicate that the 
protease Yama fulfills these criteria. The predicted protein 
sequence of Yama suggested it would be a Cys protease 
of the CED-3/ICE family and that it would have specificity 
for cleavage after Asp residues (Fernandes-Alnemri et al., 
1994), two properties that are in common with the activity, 
designated priCE, that cleaves PARP in a cell-free system 
(Lazebnik et al., 1994). We now show by in vitro reconstitu- 
tion employing purified components that Yama is indeed 
a protease that cleaves PARP (Figure 1). The specificity 
of cleavage to the signature 85 kDa fragment indicates 
that Yama might play a similar role in vivo, since the char- 
acterized members of the CED-3/ICE family have tightly 
restricted substrate specificities. ICE, for example, cleaves 
pro-lL-113 but not pro-lL-l(z (Howard et al., 1991), even 
though the latter possesses several potential Asp sites for 
cleavage. Further, as shown previously (Lazebnik et al., 
1994) and confirmed here, ICE did not cleave PARP (Fig- 
ure 1). Since PARP cleavage is a biochemical event ob- 
served in virtually every form of PCD examined (Kauf- 
mann, 1989; Kaufmann et al., 1993; M. T. and V. M. D., 
unpublished ata), the protease responsible might be ex- 
pected to play a central, universal role in mammalian 
apoptosis, a role perhaps akin to that of CED-3 in C. ele- 
gans. At this juncture, Yama is a candidate for such a 
protease. Additional studies will be required, however, be- 
fore Yama can be definitively implicated as a death prote- 
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Figure 6. CrmA, but Not Mutant CrmA, Blocks Fas- and TNF-Induced 
Cell Death 
(Top) The indicated MCF7 stably transfected clones were either kept 
untreated (UnRx) or treated with TNF (40 ng/ml) for 18 hr, following 
which cells were fixed and stained with propidium iodide and nuclear 
morphology examined by confocal microscopy. CrmA afforded signifi- 
cant protection from TNF-induced apoptosis, whereas both vector- 
transfected and mutant CrmA-expressing lines were ensitive to TNF- 
induced apoptosis. 
(Bottom) (Left) The indicated B JAB stably transfected clones wer  
quantitatively assessed for their sensitivity o Fas-induced PCD using 
an acridine orange-based apoptosis assay as described in Experimen- 
tal Procedures. Mutant CrmA-expressing cell lines w re uniformly 
sensitive, whereas CrmA expression afforded significant protection. 
(Right) The indicated MCF7 stably transfected clones were quantita- 
tively assessed for their susceptibility o TNF-induced cell death as 
described in Experimental Procedures. 
ase. These will include determining whether germline in- 
activation of Yama produces a phenotype analagous to 
that of the ced-3 mutant in C. elegans. 
The finding that CrmA inhibits the proteolytic activity 
of Yama (Figure 3) is significant, as it suggests that the 
well-documented ability of CrmA to inhibit apoptosis (Gag- 
liardini et al., 1994; Tewari and Dixit, 1995; Wang et al., 
1994; Boudreau et al., 1995) might be explained by its 
inhibition of Yama. Also, the finding that CrmA inhibits 
PARP cleavage in vivo is consistent with its inhibiting 
Yama. In this context, it is important to note that CrmA 
does not appear to be a general inhibitor of CED-3/ICE- 
family proteases given its inability to inhibit ICH-1 (Wang 
et al., 1994). 
Importantly, our studies indicate that Yama is a zymo- 
gen that requires proteolytic activation (Figure 1). This has 
important ramifications, as it suggests a mode of regula- 
tion. Yama is likely synthesized as an inactive proenzyme 
that is activated by another protease during apoptosis. 
Hence, a role for a second protease, likely also Asp spe- 
cific, is suggested. As our studies indicate that ICE itself 
can fulfill this role in vitro (Figure 1), this provides a possible 
explanation of how overexpression of exogenous ICE in- 
duces apoptosis in mammalian cells (Miura et al., 1993). 
However, since the Ice knockout mice have no overt de- 
fects in apoptosis (Li et al., 1995), it is likely that endoge- 
nous ICE is not a universal upstream proteolytic regulator 
of Yama in vivo. Nevertheless, since Yama is likely acti- 
vated by cleavages at specific Asp residues, other mem- 
bers of the ICE family, such as ICH-1L/Nedd2, are po- 
tential candidates for this regulatory role. One cannot 
discount the possibility that different proteases may regu- 
late Yama in different forms of apoptosis. Indeed, a second 
report on the germline inactivation of ICE found no overt 
defects in PCD except for one system: Fas-induced 
apoptosis of thymocytes (Kuida et al., 1995). ICE may not 
play a general role in even Fas-induced apoptosis, how- 
ever, since the expected Ipr phenotype (resulting from a 
defect in Fas-mediated peripheral T cell deletion) was not 
observed in the mice. 
Taken together, the data presented are consistent with 
the cell death pathway being a proteolytic cascade in 
which apoptotic signals from diverse stimuli converge to 
activate proteolytically a common protease, perhaps Yama, 
that in turn cleaves PARP and probably other death sub- 
strates. Indeed, additional substrates cleaved during 
apoptosis have been identified recently, and one in partic- 
ular, the 70 kDa protein component of the U 1 small nuclear 
ribonucleoprotein, is cleaved by an activity that has char- 
acteristics of a Cys protease (Casciola-Rosen et al., 1994). 
It will be important o determine whether this cleavage can 
be mediated by Yama. The identification of Yama/CPP32~ 
as a CrmA-inhibitable protease that cleaves PARP rep- 
resents a focus point that may be useful for identifying 
other upstream and downstream components of the death 
pathway. 
Experimental Procedures 
Cloning of a cDNA Encoding Yama 
The cDNA clone (b4HB3MA-COT8-HAP-Ft280 5') corresponding to 
EST T10341 was provided by M. Bento Soares (Columbia University) 
and used to screen a random-primed cDNA library constructed from 
human umbilical vein endothelial cells treated with TNF and cyclohexi- 
mide. Double-stranded DNA sequencing revealed an open reading 
frame, designated Yama, of 277 amino acids that was identical to that 
of CPP3213 (Fernandes-Al~emri et al., 1994). Although the predicted 
protein sequence of Yama was identical to that of CP P32~, the nucleo- 
tide sequence of the two pen reading frames differed at twopositions, 
most likely representing sequence polymorphisms. 
Expression and Purification of Hiss-Tagged Yama 
A 2.3 kb NcoI-BamHI fragment from the Yama cDNA described above 
was ligated into a vector (pTM1) that contained an N-terminal Hise 
fusion to facilitate purification. This construct contained the His6 tag 
followed by the complete coding region of Yama along with 1800 bp of
3' untranslated DNA. Coupled transcription/translation was performed 
with the TNT kit (Promega) according tothe recommendations of the 
manufacturer with modifications. In brief, 4 .~gof plasmid DNA was 
incubated for 1 hr at 31 °C in a total volume of 400 p.I containing the 
kit reaction mixes and 160 ~Ci of translation-grade [3~S]Met. The trans- 
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lation reaction was diluted 1:20 with 20 mM HEPES buffer (pH 7.4), 
loaded onto an equilibrated 500 p.I DEAE-Sepharose (Pharmacia) col- 
umn, and then washed with 8 ml of HEPES buffer. The column was 
eluted with 5 ml of 20 mM HEPES, 0.5 M NaCI. This eluate was loaded 
onto a 300 p.I nickeI-NTA column (Qiagen) and then washed with 5 
ml of reaction buffer (50 mM HEPES [pH 7.4], 0.1 M NaCI, 0.1% 
CHAPS, and 10o/0 sucrose). The protein was eluted five times with 
400 p.I fractions of reaction buffer containing 50 mM imidazole. 
Activation of Yama and in Vitro ReconsUtution Experiments 
Purified Yama (20 p.I) was activated by incubating at 37°C for 4 hr 
with 1.5 pmol of ICE in reaction buffer supplemented with DTT (10 
raM) in a total volume of 25 p.I, after which 30 p,I of reaction buffer was 
added and the reaction incubated at 37°C for an additional 15 rain. 
Following activation, 30 p.I of either control reaction buffer or reaction 
buffer containing 270 pmol of recombinant His6-tagged CrmA or 270 
pmol of recombinant Hise-tagged mutant CrmA was added and allowed 
to incubate at 37 ° C for 30 min. The recombinant proteins as well as the 
control buffer had been preincubated with DTT (2 mM) to preactivate 
CrmA. Following the 30 min incubation, 2 ~1 (0.586 I~g) of purified 
PARP was added, and the DTT concentration was raised to 10 mM, 
following which the reaction was allowed to proceed for 2 hr at 37°C. 
The control reaction of PARP alone was carried out under identical 
conditions, except that no Yama, ICE, or CrmA proteins were added 
during the procedure. The ICE and PARP reaction was carried out 
identically as well, except that no Yama or CrmA proteins were added 
during the procedure. 
Following the incubation with PARP, one fifth of each reaction sam- 
ple was analyzed by immunoblotting using anti-PARP monoclonal anti- 
body C-2-10 as described later. Additionally, an equivalent amount 
of each sample was resolved by SDS-PAGE and analyzed using a 
Molecular Devices phosphorimager to assess the state of radiolabeled 
Yama present in the reaction. Purified ICE was a gift of N. Thornberry 
(Merck). PARP was purified as described previously (Zahradka and 
Ebisuzaki, 1984). 
CrmA Immunoprecipitation to Detect Complex 
Formation with Yama 
Reactions were assembled by combining 20 i11 of [35S]Met-labeled 
pro-Yama or ICE-activated Yama with either 358 pmol of native CrmA 
or 358 pmol of mutant CrmA protein. Each reaction was diluted to a 
final volume of 80 i11 in reaction buffer. Complex formation was allowed 
to occur at 37°C for 30 min. An aliquot (10 I~1) of each reaction was 
resolved by SDS-PAGE and subjected to phosphorimaging to visual- 
ize the radiolabeled pro-Yama or activated Yama. A separate aliquot 
(35 i11) fo each reaction was diluted to 1 ml in PBS-TDS (O'Rourke et 
al., 1992) and immunoprecipitated using 25 p.I of the rabbit polyclonal 
CrmA antiserum (described later in this section). Immunoprecipitation 
was carried out as described previously (O'Rourke et al., 1992), and 
precipitates were resolved by SDS-PAGE and subjected to phos- 
phorimaging analysis to detect he presence of radiolabeled pro-Yama 
or activated Yama. Coomassie blue staining of the gel revealed that 
equivalent amounts of native CrmA and mutant CrmA were precipi- 
tated by the CrmA antiserum (data not shown). 
Generation of Mutant CrmA Plasmids for Eukaryotic, 
Bacterial, and In Vitro Expression 
A four-primer PCR-based method (Higuchi etal., 1988) was employed 
to convert codon 291 in the crmA gone from Thr to Arg. Initially, two 
independent PCRs were performed using the plasmid pcDNA3/crmA 
(lewari and Dixit, 1995) as template. One reaction consisted of both 
an upstream primer (primer A) corresponding to nucleotides 682-711 
of the crmA coding sequence (with nucleetide 1 representing the first 
nucleotide of the initiator Met codon) and of a downstream mutagenic 
primer (primer M2) complementary to nucleotides 853-896. Primer 
M2 contained a G to A transition that eliminated a Pstl site and base 
changes that altered codon 291 to encode Arg instead of Thr and, 
additionally, introduced a diagnostic Nrul site. The second PCR used 
an upstream sense mutagenic primer (primer Mr) complementary to 
primer M2 and a downstream primer (primer B) complementary to the 
last 26 nucleotides of the crmA coding region with custom Xbal and 
Xhol sites. The PCR products were gel purified, combined, denatured 
by boiling, and annealed by slow cooling to room temperature. Follow- 
ing a 10 min extension reaction, PCR was carried out using the flanking 
primers A and B. The amplification product was digested with Clal 
(cuts at nucleotide 692 in the crmA coding sequence) and Xbal and 
cloned into pcDNA3/crmA that had been similarly digested. The muta- 
tion was verified by DNA sequencing, as were all segments derived 
by PCR amplification. This recombinant plasmid was designated 
pcDNA3/crmA mutant. 
The sequences of oligonucleotide primers were as follows: primer 
A, 5'-GCT ATG TTT ATC GAT GTG CAC ATT CCC AAG; primer M2, 
5'-GCA CAA GTT GCT GCG GCT GCT TCG CGA TAC TCT TCA TTG 
ACA TC; primer B, 5'-GCT CTA GAC TCG AGT TAA TTA GIF GTT 
GGA GAG CAA TAT C; primer M1,5'-GAT GTC AAT GAA GAG TAT 
CGC GAA GCA GCC GCA GCA ACT TGT GC. 
For purposes of in vitro transcription and translation, the native crmA 
gone and its mutant version were digested with Ncol and Xhol and 
ligated into a plasmid based on pTM1 (Moss et al., 1990) that encoded 
an in-frame N-terminal Met-His6 tag to facilitate purification. The cod- 
ing sequence started with the initiator Met, followed by His6, a Ser, 
and then the entire coding region of crmA or the mutant. 
For expression in E. coil, the native and mutant crmA genes in pTM1 
were digested with Ncol and Xhol and ligated into a derivative of the 
isopropyl-l-thio-13-D-galactopyranoside (IPTG)-inducible plasmid pFLAG 
(IBI) that contained the same His6 fusion tag. Additionally, the crmA 
gene from pcDNA3/crmA (Tewari and Dixit, 1995) was subcloned into 
the Ncol-Xhol-digested pGSTag bacterial expression vector (Dr. H. 
Dressier, Massachusetts General Hospital) (Ron and Dressier, 1992), 
generating a chimeric glutathione S-transferase (GST)-CrmA open 
reading frame. 
Preparation of GST-CrmA Fusion Protein and Generation 
of Rabbit Polyclonal Antiserum 
Antibodies were raised against recombinant CrmA fusion proteins. 
Initial immunization was with the His6-tagged CrmA recombinant pro- 
tein, and subsequent immunizations were with a GST-CrmA fusion 
protein produced as described previously (Hu et al., 1994). In brief, 
the BL21pLysS E. coil strain was transformed with pGSTag-CrmA 
plasmid, and production of fusion protein was induced in culture by 
the addition of IPTG to 50 ~M. Following a 1.5 hr incubation at 25°C, 
the cells were recovered by centrifugation, resuspended in lysis buffer 
(20 mM Tris [pH 8.0], 0.5 M NaCI, 10% glycerol, 1 mM PMSF, 1 mg/ 
ml leupeptin, 1 mg/ml aprotinin, 10 mg/ml soybean trypsin inhibitor, 
1 mg/ml pepstatin, and 0.1% Triton X-100), sonicated, clarified by 
centrifugation, and adsorbed to glutathione-agarose beads (Sigma). 
Soluble GST-CrmA fusion protein was eluted by incubating with 5 
mM free glutathione (Sigma). Typical yield of fusion protein was 1 mg 
per liter of bacterial culture. Immunization of rabbits and screening of 
antisera were as previously described (O'Rourke etal., 1992). 
Expression and Purification of Recombinant His6-Tagged 
CrmA Proteins from E. coil 
E. coil strain TG1 transformed with either the His6-CrmA or Hisr  
mutant CrmA construct was induced with IPTG for 3 hr and harvested, 
and the cells were lysed by sonication and pelleted by centrifugation. 
The supernatant containing soluble CrmA was filtered through a 0.22 
p,m filter, loaded onto a 2 ml nickeI-NTA column (Qiagen), and washed 
with 50 mM Tris (pH 8.0) containing 0.5 M NaCI. CrmA was eluted 
with 50 mM Tris, 50 mM imidazole (pH 8.0), containing 0.1 M NaCI. This 
material was diluted with 9 vol of 20 mM HEPES (pH 7.4) containing 2 
mM DTT and applied to a 2 ml column of DEAE-Sepharose. This 
column was developed with a linear gradient of 0-1 M NaCI in 20 mM 
HEPES buffer (pH 7.4), and CrmA was eluted at approximately 0.4 M 
NaCI to give a yield of 4 mg of protein from 6 liters of culture. The 
material was greater than 95% pure as estimated by Coomassie blue 
staining and was stored at -70°C until use. In all experiments using 
this material, the CrmA was treated with 2 mM DTT for 5 min immedi- 
ately before use. This resulted in CrmA with the highest inhibitory 
activity. 
In Vitro Assay of ICE Inhibition by Recombinant CrmA 
or Mutant CrmA Protein 
To assay for inhibition, 44 ng of purified ICE was activated with 10 
mM DTT for 5 min at room temperature and then incubated at 37°C 
with various amounts of purified CrmA or mutant CrmA protein in a 
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total volume of 95 Id of reaction buffer: 20 mM HEPES buffer (pH 7.4) 
containing 100 mM NaCI, 0.5% NP-40, and 10 mM DTT. After 15 rain, 
5 ~1 of a 10 mM stock in DMSO of Boc-Ala-Ala-Pro-Asp-p-nitroanilide 
was added to determine the residual ICE activity by observing the 
release of p-nitroaniline at 410 nm using a Molecular Devices Vrn,x 
plate reader operating in the kinetic mode. The data were expressed 
as the reaction velocity in the presence of inhibitor (vi) divided by the 
velocity in its absence (Vo), which represents residual ICE activity. The 
data represent he mean and standard deviations of values derived 
from two independent experiments. Purified recombinant human ICE 
was supplied by N. Thornberry (Merck). 
In Vitro Transcription/Translation of CrmA and Mutant CrmA 
Coupled transcription/translation was performed using the TNT kit 
from Promega according to the recommendations of the manufacturer. 
In brief, 0.5 p_g of plasmid DNA was incubated for 1 hr at 31°C in a 
total volume of 50 id containing the kit reagents and 20 I~Ci of transla- 
tion grade [~S]Met, Once translated, the reaction mix was either used 
immediately or stored at -20°C until needed. 
Gel Shift Assays to Detect Complex Formation between ICE 
and CrmA or Mutant CrmA 
Serpin reactions with target proteases can be analyzed by gel shift 
analysis using purified proteinases and [~S]Met-labeled serpins pro- 
duced by in vitro translation (Komiyama et al., 1994a, 1994b). In vitro 
transcribed and translated CrmA or mutant CrmA was diluted with an 
equal volume of 50 mM HEPES buffer (pH 7.4) containing 100 mM 
NaCI, 10% sucrose, and 0.1% CHAPS. The diluted lysates (10 pJ) 
were incubated with 10 ~1 of consecutive 3-fold dilutions of ICE in the 
same buffer containing 10 mM DTT for 30 min at 37°C. Samples were 
then resolved by native gel electrophoresis and visualized using a 
Molecular Devices phosphorimager. 
TUG-PAGE 
In vitro translated CrmA or mutant CrmA protein was subjected to 
electrophoresis in TUG-polyacrylamide gels (0-8 M) as previously 
described (Goldenberg, 1989; Mast et al., 1991). The gels were dried 
and analyzed using a Molecular Devices phosphorimager. 
Stable Transfection of BJAB and MCF7 Ceils 
MCF7 or B JAB cells were electroporated with pcDNA3/crmA mutant 
plasmid and stable clonal cell lines generated as previously described 
(Tewari and Dixit, 1995). 
Cell Culture 
MCF7 cells, B JAB cells, and derived vector and crmA stable transfec- 
rants (Tewari and Dixit, 1995), along with the mutant CrmA-transfected 
stable lines generated in this study were maintained in RPMI 1640 
medium with 10% heat-inactivated fetal bovine serum (Hyclone), 
L-glutamine, penicillin/streptomycin, onessential amino acids, and 
additionally supplemented with G418 sulfate (GIBCO BRL-Life Tech- 
nologies) to 500 ~g/ml for MCF7 transfectants and 3 mg/ml for BJAB 
transfectants. 
Cell Death Assays 
Apoptosis was quantitated using an assay described previously (Tew- 
ari and Dixit, 1995) that involves counting of apoptotic and nonapop- 
totic cells, with nuclear morphology visualized by fluorescence micros- 
copy of cells stained with DNA-binding dyes (propidium iodide for 
MCF7 cells and acridine orange for B JAB cells). Laser-scanning confo- 
cal microscopy was carried out as previously described (Tewari and 
Dixit, 1995). 
Treatment with Anti-Fas or TNF and Preparation 
of Cell Lysates for PARP Analysis 
MCF7 cells or derived transfectants were plated in 100 mm dishes at 
a concentration of 2 x 106 cells per dish. On day 2, cells were treated 
with TNF at 40 ng/ml for the indicated time periods. Following a PBS 
rinse, cells were harvested by scraping into 15 ml PBS and protease 
inhibitors (1 mM PMSF, 0.5 mg/ml aprotinin, 0.5 mg/ml antipain, and 
0.5 mg/ml pepstatin), recovered by centrifugation, and lysed in 2.5 ml 
of sample buffer (50 mM Tris-HCI [pH 6.8], 6 M urea, 60/o 2-mer- 
captoethanol, 3% SDS, and 0.003% bromophenol blue). In cases in 
which nonadherent cells were present in the culture medium (e.g., at 
later timepoints), floating cells were also harvested by centrifugation 
and combined with the adherent cell pellet before lysis in sample 
buffer. 
B JAB cells or derived transfectants were aliquoted at a concentra- 
tion of 5 x 10 s cells/ml into 6-well dishes, with 4 ml in each well. The 
following day, cells were treated with anti-Fas antibody (250 ng/ml) 
for the indicated time periods, harvested by centrifugation, washed 
once with PBS and protease inhibitors, and lysed in 2 ml of sample 
buffer. 
Western Blotting 
For detection of CrmA, whole-cell ysates (2 x 105 cells per lane) were 
resolved by SDS-PAGE, transferred to nitrocellulose, and processed 
as previously described (Shao et al., 1994). The GST-CrmA rabbit 
antiserum was used at a dilution of 1:1,000, and a horseradish peroxi- 
dase-conjugated onkey anti-rabbit secondary antibody (Amersham 
Life Sciences) was used at a 1:15,000 dilution. Visualization of signal 
was by ECL (Amersham). 
Immunoblotting of lysates for PARP was carried out as previously 
described (Desnoyers et al., 1994). The anti-PARP mouse monoclonal 
antibody was used at a dilution of 1:10,000, and the secondary anti- 
body, an anti-mouse immunoglobulin labeled with horseradish peroxi- 
dase, was used at a dilution of 1:1000. Visualization of signal was also 
by ECL. 
TNF, Anti-Fas Antibody, and Anti-PARP Antibody 
Recombinant TNF (specific activity, 6.27 x 107 U/rag) was a gift from 
Genentech (South San Francisco, CA). Anti-Fas monoclonal antibody 
(clone CH-11; IgM) was obtained from PanVera (Madison, WI). The 
anti-PARP monoclonal antibodywas clone C-2-10, which, as described 
previously (Lamarre et al., 1988), recognizes an epitope near the 
N-terminal end of PARP, located between amino acids 215 and 375. 
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